Russia to begin human trials of its first mRNA melanoma vaccine in October 2025
According to recent reports, Russia’s Gamaleya Center, the developer of the Sputnik V COVID-19 vaccine, is planning to initiate human trials for its personalized mRNA melanoma vaccine in September-October 2025.
This innovative vaccine is tailored to individual tumor genetics using Artificial Intelligence (AI) to instruct the immune system to recognize and eliminate cancer cells.
The vaccine, developed collaboratively by the Gamaleya Center, the A.A. Herzen Moscow Research Institute of Oncology, and the N.N. Blokhin National Medical Research Center of Oncology, is part of a broader Russian initiative to advance cancer treatment, according to trial.medpath.com.
The Russian government plans to provide this personalized mRNA cancer vaccine free of charge to its citizens.
Preclinical trials have shown promising results, including the suppression of tumor development and potential metastases in animal models.
